LASS5 Antibody
| Code | Size | Price |
|---|
| PSI-4697-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4697-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
LASS5 Antibody: Trh4, LASS5, Ceramide synthase 5, LAG1 longevity assurance homolog 5, CerS5
Application Note:
LASS5 antibody can be used for detection of LASS5 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
LASS5 Antibody: The LASS (longevity assurance homolog) family members represent a subgroup of the homeobox gene family and are highly conserved from yeasts to mammals. Six members of this family of proteins have been characterized (LASS1-6) and all are involved in ceramide synthesis during cell growth regulation and cancer differentiation. LASS5, also called Trh4, is a 392 amino acid endoplasmic reticulum, multi-pass membrane protein. Functioning as a dihydro-ceramide synthase, LASS5 is involved in the production of sphingolipids containing mainly one fatty acid donor (N-linked palmitoyl-ceramide) in a fumonisin B1-independent manner. It uses palmitoyl-CoA as an acyl donor and is involved in the synthesis of C14, C16 and C18-ceramide. LASS5 is the most abundantly expressed and predominant ceramide synthase isoform in lung epithelia. Recent studies show that LASS5 partially correct growth and apoptosis.
Background References:
- Riebeling C, Allegood JC, Wang E, et al. Two mammalian longevity assurance gene (LAG1) family members, Trh1 and Trh, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J. Biol. Chem.2003; 278:43452-9.
- Lahiri S and Futerman AH. LASS5 is a bona fide dihydroceramide synthase that selectively utilizes palmitoyl-CoA as acyl donor. J. Biol Chem.2005; 280:33735-8.
- Spassieva S, Seo JG, Jiang JC, et al. 2006. Necessary role for the LAG1p motif in (dihydro)ceramide synthase activity. J. Biol. Chem.2006; 281:33931-8.
- Xu Z, Zhou J, McCoy DM, et al. LASS5 is the predominant ceramide synthase isoform involved in de novo sphingolipid synthesis in lung epithelia. J. Lipid Res.2005; 46:1229-38.
Buffer:
LASS5 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
LASS5 antibody was raised against a 18 amino acid synthetic peptide near the amino terminus of the human LASS5.
The immunogen is located within amino acids 90 - 140 of LASS5.
The immunogen is located within amino acids 90 - 140 of LASS5.
NCBI Gene ID #:
91012
NCBI Official Name:
ceramide synthase 5
NCBI Official Symbol:
CERS5
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_671723
Protein GI Number:
22218345
Purification:
LASS5 Antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
SPECIFICITY:
Multiple isoforms of LASS5 are known to exist. This antibody may cross-react with the highly homologous LASS6.
Swissprot #:
Q8N5B7
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | LASS5 Peptide | PSI-4697P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|